Multimodal Study About Absence of Dp140 in Becker Muscular Dystrophy: Brain-muscle Imaging, Cognition and Muscle Function (MyoBrain-BMD)
Monitoring patients with neuromuscular disorders is crucial but doesn't always allow for a sufficiently specific approach to all aspects of the condition. However, in the event of future treatment, it is essential for clinical and research teams to have as much information as possible about the disease, particularly regarding its physical, physiological, biological, and neurological aspects.
In this context, it was consider as vital to investigate in greater depth the links between the presence of certain dystrophin isoforms in patients and their potential impacts on cognitive, neurological, and muscular function. The results of this study could serve as a reference for future research and improve the understanding and management of this disease.
All of this data will allow for a precise evaluation of the effects of a potential treatment on the progression of the disease.
연구 개요
상태
상태
정황
정황
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Harmen REYNGOUDT, PhD
- 전화번호: 01 42 16 58 91
- 이메일: h.reyngoudt@institut-myologie.org
연구 장소
-
-
-
Paris, 프랑스, 75651
- Institute of Mythology
-
연락하다:
- Tanya STOJKOVIC, Md
- 전화번호: 01 42 16 37 76
- 이메일: t.stojkovic@institut-myologie.org
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Genetically confirmed diagnosis of Becker muscular dystrophy
- Ambulant
- Signed ICF
Exclusion Criteria:
- Individuals presenting contraindications to MRI
- History of allergy to contrast product
- Individuals with history of neurological diseases interfering with the study
Individuals with concomitant medical conditions that could interfere with the study outcomes
- subjects who suffer from any type of cancer (or on cancer treatment)
- obese subjects: BMI>35
- subjects with cardiac (left-ventricular ejection fraction <40%) and/or respiratory insufficiency (forced vital capacity < 50%) and/or normal ECG
- Individuals who are not yet or insufficiently stabilized on psychiatric medication
- Any medical and social condition that may interfere with the study at the discretion of the medical coordinator
- Guardianship
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
|---|
|
건강한 과목
|
|
BMD patients Dp140+
Dp140+
|
|
BMD patients Dp140-
Dp140-
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Brain volume
기간: 2 years
|
Measurement of grey and white matter volume (in mm3) using brain MRI sequences.
|
2 years
|
|
Brain cortical thickness
기간: 2 years
|
Measurement of cortical thickness (in mm) using brain MRI sequences.
|
2 years
|
|
Brain water motion
기간: 2 years
|
Measurement of diffusion-based values, including apparent diffusion coefficient (in m2/s) and fractional anisotropy (unitless) using diffusion-weighted MRI sequences.
|
2 years
|
|
Brain iron metabolism
기간: 2 years
|
Measurement of brain iron metabolism using MRI-based quantitative susceptibility mapping (measured in parts per million).
|
2 years
|
|
Brain function: resting-state and following task
기간: 2 years
|
Measurement of resting-state brain function (default-mode-network) using functional MRI.
Measurement of brain activation using fMRI following fronto-executive task (Stroop test).
|
2 years
|
|
Intelligence test
기간: 2 years
|
Evaluation of intelligence using Wechsler Scale of Intelligence (WAIS-4).
|
2 years
|
|
Psychological evaluation of depression
기간: 2 years
|
Psychological evaluation using Beck Depression Inventory-II (BDI-II).
|
2 years
|
|
Psychological evaluation of anxiety
기간: 2 years
|
Psychological evaluation using State-Trait Anxiety Inventory-2 (STAI-Y2).
|
2 years
|
|
Psychological evaluation of ADHD
기간: 2 years
|
Psychological evaluation using Connors Adult Rating Scale.
|
2 years
|
|
Neuropsychological evaluation of memory for attention and cognitive processing
기간: 2 years
|
Neuropsychological cognitive evaluation of memory for attention and cognitive processing using Free and Cued Selective Reminding Test (FCSRT).
|
2 years
|
|
Neuropsychological evaluation of visual memory and executive function
기간: 2 years
|
Neuropsychological cognitive evaluation of visual memory and executive function using Rey-Osterrieth Complex Figure Test (ROCF).
|
2 years
|
|
Neuropsychological evaluation of visual attention and task switching
기간: 2 years
|
Neuropsychological cognitive evaluation of visual attention and task switching using Trail Making Test.
|
2 years
|
|
Neuropsychological evaluation of inhibition
기간: 2 years
|
Neuropsychological cognitive evaluation of inhibition using Stroop Color and Word Test.
|
2 years
|
|
Neuropsychological evaluation of verbal functioning
기간: 2 years
|
Neuropsychological cognitive evaluation of verbal functioning using Phonemic verbal fluency test.
|
2 years
|
|
Neuropsychological evaluation of facial expressions.
기간: 2 years
|
Neuropsychological cognitive evaluation of facial expressions using Pictures of Facial Affect test.
|
2 years
|
|
Neuropsychological evaluation of empathy
기간: 2 years
|
Neuropsychological cognitive evaluation understanding inappropriateness, speaker's intentions/motivations, speaker's belief, empathy (participant's ability to know how the character would feel), and finally story comprehension using Faux pas Recognition Test.
Empathy is also evaluated using The Interpersonal Reactivity Index.
|
2 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Evaluation of muscle disease progression
기간: 2 years
|
Evaluation of disease progression based on quantitative assessment of MRI-based muscle fat fraction (FF, in %) and residual muscle (i.e.
contractile cross-sectional area, in cm2) in lower limb (individual thigh and leg muscles).
|
2 years
|
|
Evaluation of muscle disease activity (edema, inflammation, ...)
기간: 2 years
|
Evaluation of qMRI-biomarkers sensitive to active muscle damage or disease activity such as water T2 and water T1 mapping, expressed in milliseconds (individual thigh and leg muscles).
|
2 years
|
|
Evaluation of muscle extracellular volume
기간: 2 years
|
Evaluation of extracellular volume (ECV) in muscle (unitless or %) will be assessed using qMRI-based T1 mapping before and after contrast agent injection (individual thigh and leg muscles).
|
2 years
|
|
Evaluation of energy metabolism.
기간: 2 years
|
Evaluation of energy metabolism using qMRI and 31P magnetic resonance spectroscopy.
|
2 years
|
|
Evaluation of intramuscular pH.
기간: 2 years
|
Evaluation of intramuscular pH using qMRI and 31P magnetic resonance spectroscopy.
|
2 years
|
|
Evaluation of gait endurance (timed test)
기간: 2 years
|
Evaluation of gait endurance using 6-minute walk test (6MWT) and 10-m walking test (10mWT).
|
2 years
|
|
Evaluation of exertion and dyspnea (timed test)
기간: 2 years
|
Evaluation of exertion and dyspnea using 30-second sit-to-stand test (30STS).
|
2 years
|
|
Evaluation of TUG test performance
기간: 2 years
|
Evaluation of performance at time-up-and-go test (TUG).
|
2 years
|
|
Motor Function assessment
기간: 2 years
|
Evaluation of motor function abilities using quantitative Motor Function Measurement (MFM) scale.
|
2 years
|
|
Muscle strength evaluation
기간: 2 years
|
Strength evaluation of knee extension/flexion, dorsiflexion/plantarflexion of ankle, hand grip and fingers' pinch strength using dedicated MyoTools.
|
2 years
|
|
Evaluation of quality of life
기간: 2 years
|
Evaluation of The "Quality of Life in genetic Neuromuscular Disease" questionnaire (QoL-gNMD).
|
2 years
|
|
Health assessment
기간: 2 years
|
Health assessment using the Health Assessment Questionnaire (HAQ).
|
2 years
|
|
Assessment of individual's activity level
기간: 2 years
|
Assessment of individual's activity level using Ricci et Gagnon Questionnaire.
|
2 years
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Blood analysis
기간: 2 years
|
Evaluation of blood biological parameters.
|
2 years
|
|
Echocardiography
기간: 2 years
|
Evaluation of left-ventricular ejection fraction (in %).
|
2 years
|
|
Pulmonary function
기간: 2 years
|
Evaluation of Pulmonary Function using Forced Vital Capacity measurement.
|
2 years
|
공동 작업자 및 조사자
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2026-A00317-44
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .